Treatment of isolated systolic hypertension

Gordon S Stokes1

  • 1gstokes@med.usyd.edu.au

Current Hypertension Reports
|September 13, 2006
PubMed

Insights

Isolated systolic hypertension (ISH) in older adults is effectively treated with diuretics, CCBs, and angiotensin II inhibitors. These medications reduce blood pressure and cardiovascular risks, with pulse wave reflection influencing drug choice.

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Isolated systolic hypertension (ISH) is the most common hypertension type in the elderly.
  • ISH is linked to increased arterial pulse pressure, significantly influenced by pulse-wave reflection.
  • Early and magnified pulse-wave reflection contributes to elevated pulse pressure in ISH.

Purpose of the Study:

  • To evaluate the efficacy of different antihypertensive drug classes in treating ISH.
  • To determine how drug mechanisms affect pulse pressure and systolic blood pressure reduction.
  • To explore the role of pulse-wave reflection measurement in refractory ISH cases.

Main Methods:

  • Review of antihypertensive treatments for ISH, including diuretics, CCBs, angiotensin II inhibitors, and beta-blockers.
  • Analysis of drug effects on systolic blood pressure, pulse pressure, and pulse-wave reflection.
  • Consideration of applanation tonometry for assessing reflected waves in complex cases.

Main Results:

  • Diuretics, CCBs, and angiotensin II inhibitors effectively lower systolic blood pressure and reduce cardiovascular events and mortality in ISH.
  • Combination therapy may be necessary to reach a systolic blood pressure goal of < 140 mm Hg.
  • Beta-blockers show less efficacy compared to other drug classes.
  • Drug efficacy in lowering pulse pressure and systolic blood pressure correlates with their ability to reduce pulse-wave reflection.

Conclusions:

  • ISH management requires careful drug selection, considering their impact on pulse-wave reflection.
  • Applanation tonometry can guide treatment decisions for ISH refractory to standard therapies.
  • Optimizing ISH treatment involves understanding the interplay between drug action and vascular hemodynamics.

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...